Media coverage about Opko Health (NASDAQ:OPK) has trended somewhat positive recently, Accern reports. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Opko Health earned a news sentiment score of 0.07 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 45.9568429408762 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Opko Health Inc. (OPK) Short Interest Update (americanbankingnews.com)
- Opko Health, Inc. (OPK) finishes with -0.30% while stock price is worth at $3.32 – Nasdaq Fortune (press release) (nasdaqfortune.com)
- Opko Health Inc (OPK) Technical Fundamentals and Valuation – ExpertGazette (expertgazette.com)
- Grabs Dynamic Performance Momentum on Volatility- Opko Health, Inc. (NASDAQ:OPK) – Stock News Stop (stockmarketstop.com)
- Opko Health, Inc. (NASDAQ:OPK) – Hot Stock under Review – Nasdaq Journal (nasdaqjournal.com)
Several equities analysts recently commented on OPK shares. BidaskClub downgraded Opko Health from a “hold” rating to a “sell” rating in a research note on Saturday, November 11th. Zacks Investment Research downgraded Opko Health from a “hold” rating to a “sell” rating in a research note on Tuesday, November 14th. ValuEngine downgraded Opko Health from a “sell” rating to a “strong sell” rating in a research note on Thursday, March 1st. Finally, Cantor Fitzgerald set a $20.00 price objective on Opko Health and gave the company a “buy” rating in a research note on Thursday, March 1st. Four analysts have rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $13.25.
In other news, CEO Phillip Md Et Al Frost acquired 100,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 24th. The shares were acquired at an average price of $4.89 per share, for a total transaction of $489,000.00. Following the completion of the purchase, the chief executive officer now owns 3,068,951 shares in the company, valued at $15,007,170.39. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last quarter, insiders purchased 1,306,300 shares of company stock worth $4,935,197. 40.19% of the stock is owned by company insiders.
ILLEGAL ACTIVITY WARNING: This piece was reported by Ticker Report and is owned by of Ticker Report. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3254689/opko-health-opk-given-news-impact-rating-of-0-07.html.
About Opko Health
OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.
Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.